Navigation Links
Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research
Date:4/18/2011

BRIDGEWATER, N.J., April 18, 2011 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has entered into a multi-year research collaboration agreement through the Stanford University Bio-X program that supports, organizes, and facilitates interdisciplinary, collaborative and innovative research projects in the early phases of development. The research collaboration was signed today by Dr. Paul Chew, Senior Vice President, U.S. Chief Science Officer and Chief Medical Officer, sanofi-aventis U.S. during a visit to Stanford.

Under the terms of the agreement, a Stanford Bio-X and sanofi-aventis Joint Steering Committee will fund up to five programs a year.  Sanofi-aventis may also host postdoctoral fellows at the company and sanofi-aventis scientists may also be invited by Stanford faculty to be visiting scholars and to pursue research collaborations at Stanford.  To further this exchange of ideas, sanofi-aventis will fund an annual research forum that will bring together sanofi-aventis and Bio-X researchers to share knowledge and perspectives on relevant scientific matters and to discuss research projects funded through the collaboration.  

"Our approach to research and development must ensure we are at the center of the most innovative science, whether inside our own walls or through external partnerships, in order to continue to advance scientific knowledge and address patients' unmet medical needs," said Dr. Chew.  "Stanford is a world-class institution and sanofi-aventis is delighted to collaborate with its team of scientists who share a common vision of developing healthcare solutions through scientific discoveries and innovation across various disciplines.   Bio-X researchers are exploring novel approaches needed in science today to accelerate the potential for scientific breakthroughs."

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone.  Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, please visit: www.sanofi-aventis.com.  

About the Bio-X program at Stanford University

Bio-X, a joint project of Stanford University's Schools of Humanities and Sciences, Engineering, Earth Sciences and Medicine, was created in 1998 to promote interdisciplinary research in the biosciences. A portal to the Stanford biosciences and bioengineering community, Bio-X is an interdisciplinary life sciences research program that combines biology/life sciences, engineering, computer science, clinicians/clinical research, law/ethics/mathematics/statistics and physical sciences. It has 450 affiliated faculty from 50 departments.  Stanford Bio-X, through its Interdisciplinary Initiatives Program (IIP) provides seed funding — about $3 million every other year in the form of two-year grants of $150,000 — to researchers from across campus.  From inception in 2000 through the fifth round in 2010, the IIP has provided early-stage funding to 113 projects involving more than 294 faculty from dozens of departments.  These projects have resulted in the development of new technologies and more than 30 filed patents.

Media contacts:
Elizabeth Baxter
U.S. R&D Communications
Tel: (908) 981-5360
E-mail: elizabeth.baxter@sanofi-aventis.com
Sanofi-aventis: www.sanofi-aventis.us
Media Relations: Tel. : 908-981-6010
E-mail:  us.media-relations@sanofi-aventis.com
Investor Relations: Tel. : 908-981-5560
E-mail: IR@sanofi-aventis.com


'/>"/>
SOURCE sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
3. Sanofi-aventis Stands Behind the Safety of Lantus(R)
4. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
5. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
6. Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
7. Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender Offer
8. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
9. Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc.
10. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
11. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 New England Pediatric ... of an award including funding and in-kind service towards ... technology.  "Making blood draws less traumatic ... their whole hospital experience better.  We,re looking forward to ... can help improve care for the kids we treat," ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets has ... Development, Growth and Demand Forecast to 2022" report to their offering. ... The global wound care ... grow at a CAGR of 6.7% during 2016-2022 Among the ... the largest share in the global market in 2015. Among the various ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of the ... offering. ... the worldwide markets for Dental Implants in US$ Million. The report provides ... Japan , Europe , Asia-Pacific ... Annual estimates and forecasts are provided for the period ...
Breaking Medicine Technology:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... ... “Vintage and Harvest A Cultivation of Christian Love” is the creation of published author, ... his wife, Anna Marie. He and his wife are the proud parents of four ... of “Shadow and Substance.” , “Love, the agape kind, is seen as more than ...
(Date:3/23/2017)... NC & Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... public health emergency and now estimates that there could be four million Zika-related cases ... growing epidemics to date with numbers of US cases reported per year skyrocketing to ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... services to their communities, 16 more public health departments have been awarded national ... bring another 4.5 million people into the expanding network of communities across the ...
(Date:3/23/2017)... ... March 23, 2017 , ... The IoT (Internet of Things) is revolutionizing the ... huge impact on businesses and individual consumers alike. Laboratories can maximize their profit ... value anywhere from $4 trillion to $11 trillion dollars by the year 2025. McKinsey ...
Breaking Medicine News(10 mins):